Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2019 / Articles / May / Small, But Never Forgotten
Manufacture Small Molecules Technology and Equipment Contract Manufacturing Services Facilities & Equipment Technology & Manufacturing Outsourcing

Small, But Never Forgotten

A new publication will give the small molecule manufacturing community the attention and praise it deserves. Meet The Small Molecule Manufacturer.

By Stephanie Vine 05/13/2019 0 min read

Share

The best-selling drugs in the world in terms of revenue are biopharmaceuticals. But when it comes to the amount of medicines most commonly used and prescribed, small molecules have large molecules completely beat. The over-the-counter medicine market is almost exclusively made up of small molecule products but, even when considering prescriptions, the most commonly used drugs are still small molecules. Lists vary depending on the sources used but, in the US, the most commonly prescribed medicines of 2018 are typically cited as levothyroxine, lisinopril, atorvastatin, metformin hydrochloride, amlodipine besylate, metroprolol, omeprazole, simvastatin, losartan potassium and albuterol. They are small molecules.

The importance of small molecules to global health is further emphasized by the World Health Organization’s List of Essential Medicines, which includes general anesthetics, palliative care and pain medicines, antiallergics, antiinfectives, anticonvulsives, antimigraine medicines, immunosuppressants and cardiovascular medicines. What do most of the drugs on the list share in common? They are small molecules.

Small molecules also account for the lion’s share of new drug approvals; over 60 percent of new drugs approved by the FDA in 2018 were small molecules. Innovation in small molecules is not dead. So it seems a little unfair that these workhorse medicines should be continually overshadowed by the latest biologics and “advanced” therapies.

And so, to celebrate the continued leaps and bounds in the small molecule arena, we are launching a new magazine. The Small Molecule Manufacturer will focus on the people, processes and technologies driving advances in the development and manufacture of small molecule drugs – as the name suggests. You can register to receive this new publication for free here.

“But does this mean that small molecules will be excluded from The Medicine Maker from now on?” – we hear you cry! Absolutely not. We will continue to report on the trends, technologies and personalities shaping all areas of the medicine making industry. Rather, The Small Molecule Manufacturer will serve as a special community for those working with an incredibly diverse and important selection of drug products that should never be forgotten.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Stephanie Vine

Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent fourteen years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read.

More Articles by Stephanie Vine

False

Advertisement

Recommended

False

Related Content

The Final Frontier?
Small Molecules
The Final Frontier?

December 1, 2014

0 min read

The Galactic Grant Competition encourages companies to use the International Space Station for pharmaceutical R&D

Calculate – Don’t Estimate – Drug Development Costs
Small Molecules
Calculate – Don’t Estimate – Drug Development Costs

December 1, 2014

0 min read

Researchers estimate the cost of drug development at over $1 billion, while others say it’s less than $100 million. Who’s right? And how can we accurately determine the true costs?

Electrifying R&D Acceleration
Small Molecules Analytical Science
Electrifying R&D Acceleration

December 2, 2014

0 min read

Electrochemical reaction cells are finding new applications in the pharma R&D lab that could offer big time and cost savings...

United Science Stands
Small Molecules Standards & Regulation
United Science Stands

December 2, 2014

0 min read

Sitting Down With… William Chin, Executive Vice President, Scientific and Regulatory Affairs, Pharmaceutical Research and Manufacturers of America (PhRMA).

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.